Publicaciones en las que colabora con Ángel Ramírez Payer (15)

2023

  1. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

    Cancer Immunology, Immunotherapy, Vol. 72, Núm. 7, pp. 2529-2539

2021

  1. Btla/hvem axis induces nk cell immunosuppression and poor outcome in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 8

  2. Lag‐3 blockade with relatlimab (Bms‐986016) restores anti‐leukemic responses in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 9

2020

  1. Driver mutations and single copy number abnormalities identify binet stage a patients with chronic lymphocytic leukemia with aggressive progression

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-8

  2. Expression of CD47 antigen in Reed–Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 782-785

  3. Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 10

2019

  1. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling

    Frontiers in Immunology, Vol. 10

2018

  1. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia

    Frontiers in immunology, Vol. 9, pp. 2917

2017

  1. Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia

    OncoImmunology, Vol. 6, Núm. 10

2016

  1. Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: Clinical experience in three patients

    Leukemia and Lymphoma

2015

  1. On the prediction of Hodgkin lymphoma treatment response

    Clinical and Translational Oncology, Vol. 17, Núm. 8, pp. 612-619

  2. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy

    Leukemia and Lymphoma, Vol. 56, Núm. 11, pp. 3096-3102

2014

  1. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia.Correlation with progressive disease

    PLoS ONE, Vol. 9, Núm. 10

  2. Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

    BioMed Research International, Vol. 2014

2013

  1. Lenalidomide and chronic lymphocytic leukemia

    BioMed Research International, Vol. 2013